Diabetic Foot Ulcers – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Diabetic Foot Ulcers – Pipeline Review, H1 2020’, provides an overview of the Diabetic Foot Ulcers pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers

– The report reviews pipeline therapeutics for Diabetic Foot Ulcers by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Diabetic Foot Ulcers therapeutics and enlists all their major and minor projects

– The report assesses Diabetic Foot Ulcers therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alan Laboratories Inc

Anterogen Co Ltd

Aposcience AG

Aprogen Inc

APstem Therapeutics Inc

AptaBio Therapeutics Inc

Aurealis Therapeutics AG

Biofilm Pharma

Biotherapy Services Ltd

Blue Blood Biotech Corp

Canton Biotechnologies Inc

CardioVascular BioTherapeutics Inc

Celularity Inc

Chiesi Farmaceutici SpA

Chrysalis BioTherapeutics Inc

CSA Biotechnologies LLC

Cynata Therapeutics Ltd

CytoTools AG

Destiny Pharma Plc

Energenesis Biomedical Co Ltd

EyeGene Inc

FirstString Research Inc

Genentech Inc

Helixmith Co Ltd

Hoth Therapeutics Inc

Human Stem Cells Institute

Imstem Biotechnology Inc

Lakewood-Amedex Inc

Liminal BioSciences Inc

Mallinckrodt Plc

MangoGen Pharma Inc

MediWound Ltd

Mirae Cell Bio Co Ltd

NovaLead Pharma Pvt Ltd

OliX Pharmaceuticals Inc

Orbsen Therapeutics Ltd

Pherecydes Pharma SA

Promore Pharma AB

QBiotics Ltd

Remedor Biomed Ltd

RHEACELL GmbH & Co KG

Riptide Bioscience Inc

Serodus ASA

Shionogi & Co Ltd

Sinobioway Biomedical Co Ltd

Stempeutics Research Pvt Ltd

Suzhou Kintor Pharmaceutical Inc

TechnoPhage SA

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

Tissuetech Inc

Topadur Pharma AG

Transwell Biotech Co Ltd

USV Pvt Ltd

Vasomune Inc

Xenexus Pharmaceuticals Pty Ltd

Zhittya Genesis Medicine Inc

ZZ Biotech LLC

Table of Contents

Table of Contents

Introduction

Diabetic Foot Ulcers - Overview

Diabetic Foot Ulcers - Therapeutics Development

Diabetic Foot Ulcers - Therapeutics Assessment

Diabetic Foot Ulcers - Companies Involved in Therapeutics Development

Diabetic Foot Ulcers - Drug Profiles

Diabetic Foot Ulcers - Dormant Projects

Diabetic Foot Ulcers - Discontinued Products

Diabetic Foot Ulcers - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Diabetic Foot Ulcers, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Diabetic Foot Ulcers – Pipeline by Alan Laboratories Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Anterogen Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Aposcience AG, H1 2020

Diabetic Foot Ulcers – Pipeline by Aprogen Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by APstem Therapeutics Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by AptaBio Therapeutics Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Aurealis Therapeutics AG, H1 2020

Diabetic Foot Ulcers – Pipeline by Biofilm Pharma, H1 2020

Diabetic Foot Ulcers – Pipeline by Biotherapy Services Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Blue Blood Biotech Corp, H1 2020

Diabetic Foot Ulcers – Pipeline by Canton Biotechnologies Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by CardioVascular BioTherapeutics Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Celularity Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Chiesi Farmaceutici SpA, H1 2020

Diabetic Foot Ulcers – Pipeline by Chrysalis BioTherapeutics Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by CSA Biotechnologies LLC, H1 2020

Diabetic Foot Ulcers – Pipeline by Cynata Therapeutics Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by CytoTools AG, H1 2020

Diabetic Foot Ulcers – Pipeline by Destiny Pharma Plc, H1 2020

Diabetic Foot Ulcers – Pipeline by Energenesis Biomedical Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by EyeGene Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by FirstString Research Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Genentech Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Helixmith Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Hoth Therapeutics Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Human Stem Cells Institute, H1 2020

Diabetic Foot Ulcers – Pipeline by Imstem Biotechnology Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Lakewood-Amedex Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Liminal BioSciences Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Mallinckrodt Plc, H1 2020

Diabetic Foot Ulcers – Pipeline by MangoGen Pharma Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by MediWound Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Mirae Cell Bio Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by NovaLead Pharma Pvt Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by OliX Pharmaceuticals Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Orbsen Therapeutics Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Pherecydes Pharma SA, H1 2020

Diabetic Foot Ulcers – Pipeline by Promore Pharma AB, H1 2020

Diabetic Foot Ulcers – Pipeline by QBiotics Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Remedor Biomed Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by RHEACELL GmbH & Co KG, H1 2020

Diabetic Foot Ulcers – Pipeline by Riptide Bioscience Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Serodus ASA, H1 2020

Diabetic Foot Ulcers – Pipeline by Shionogi & Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Sinobioway Biomedical Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Stempeutics Research Pvt Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Suzhou Kintor Pharmaceutical Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by TechnoPhage SA, H1 2020

Diabetic Foot Ulcers – Pipeline by TGV-Inhalonix Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Therapeutic Systems Research Laboratories Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Tissuetech Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Topadur Pharma AG, H1 2020

Diabetic Foot Ulcers – Pipeline by Transwell Biotech Co Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by USV Pvt Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Vasomune Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by Xenexus Pharmaceuticals Pty Ltd, H1 2020

Diabetic Foot Ulcers – Pipeline by Zhittya Genesis Medicine Inc, H1 2020

Diabetic Foot Ulcers – Pipeline by ZZ Biotech LLC, H1 2020

Diabetic Foot Ulcers – Dormant Projects, H1 2020

Diabetic Foot Ulcers – Dormant Projects, H1 2020 (Contd..1), H1 2020

Diabetic Foot Ulcers – Dormant Projects, H1 2020 (Contd..2), H1 2020

Diabetic Foot Ulcers – Dormant Projects, H1 2020 (Contd..3), H1 2020

Diabetic Foot Ulcers – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Diabetic Foot Ulcers, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports